Relaxant effects of selected sildenafil analogues in the rat aorta

Abstract A new series of sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazine with chiral amino group has been synthesized and characterized. The compounds were tested for their relaxant effects in the rat aorta. Evaluation of prepared derivatives demonstrated that compound (8a) is probably a non-selective phosphodiesterase (PDE) inhibitor, as it induced aortic relaxation through endothelium-independent mechanism.

[1]  C. Supuran,et al.  New approaches to the synthesis of sildenafil analogues and their enzyme inhibitory activity. , 2015, Bioorganic & medicinal chemistry.

[2]  W. Voelter,et al.  Synthesis of pyrazolo[4,3-e][1,2,4]triazine sulfonamides, novel Sildenafil analogs with tyrosinase inhibitory activity. , 2014, Bioorganic & medicinal chemistry.

[3]  A. Bella,et al.  Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. , 2007, European urology.

[4]  M. Mojzych,et al.  Transformations of phenylhydrazones of 5-acyl-1,2,4-triazines to pyrazolo[4,3-e][1,2,4]triazines or 4-cyanopyrazole† , 2007 .

[5]  J. Y. Lee,et al.  3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[6]  J. Kotera,et al.  Overview of PDEs and Their Regulation , 2007, Circulation research.

[7]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[8]  C. Lugnier.  Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. , 2006, Pharmacology & therapeutics.

[9]  J. B. Salom,et al.  Relaxant effect of sildenafil in the rabbit basilar artery. , 2006, Vascular pharmacology.

[10]  Bin-Nan Wu,et al.  Aortic Smooth Muscle Relaxants KMUP-3 and KMUP-4, Two Nitrophenylpiperazine Derivatives of Xanthine, Display cGMP-Enhancing Activity: Roles of Endothelium, Phosphodiesterase, and K+ Channel , 2005, Journal of cardiovascular pharmacology.

[11]  Jingshan Shen,et al.  Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives. , 2005, Bioorganic & medicinal chemistry letters.

[12]  Y. Lo,et al.  Endothelium-dependent and -independent vasorelaxation by a theophylline derivative MCPT: roles of cyclic nucleotides, potassium channel opening and phosphodiesterase inhibition. , 2005, Life sciences.

[13]  R. Cote.  Characteristics of Photoreceptor PDE (PDE6): similarities and differences to PDE5 , 2004, International Journal of Impotence Research.

[14]  M. Mojzych,et al.  One-Step Synthesis and Regioselective Alkylation of Substituted 1H-Pyrazolo[4,3-e][1,2,4]triazine (II). , 2004 .

[15]  M. Mojzych,et al.  One-Step Synthesis and Regioselective Alkylation of Substituted 1H-Pyrazolo {4,3-e] [1,2,4] triazine , 2003 .

[16]  G. Guillaumet,et al.  Palladium-catalyzed 3-Thiomethyltriazine-boronic Acid Cross Coupling: Easy Access to 3-Substituted-1,2,4-triazines , 2002 .

[17]  C. Lugnier,et al.  Role of cyclic nucleotide phosphodiesterase isoenzymes in contractile responses of denuded rat aorta related to various Ca2+ sources , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[18]  M. Mojzych,et al.  A New Synthesis of Pyrazolo- [4,3-e][1,2,4]triazines via Acid Promoted Ring Closure of the Phenylhydrazones of 5-Acyl-1,2,4-triazines , 2000 .

[19]  J. Beavo,et al.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. , 2000, Current opinion in cell biology.

[20]  A. Rykowski,et al.  A Concise Route to a Key Intermediate in the Total Synthesis of Sempervirine1 , 1996 .

[21]  M. Mąkosza,et al.  Reaction of 1,2,4-triazines with nitronate anions, direct nucleophilic acylation of 1,2,4-triazines , 1984 .